Login Register Cart 0
Generic placeholder image

Current Drug Metabolism

Editor-in-Chief

ISSN (Print): 1389-2002
ISSN (Online): 1875-5453

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Clinical Pharmacokinetics of Propranolol Hydrochloride: A Review

Author(s): Muhammad Nasir Kalam , Muhammad Fawad Rasool , Asim Ur Rehman and Naveed Ahmed *

Volume 21, Issue 2, 2020

Page: [89 - 105] Pages: 17

DOI: 10.2174/1389200221666200414094644

Price: $65

Abstract

Background: Nobel laureate Sir James Black’s molecule, propranolol, still has broad potential in cardiovascular diseases, infantile haemangiomas and anxiety. A comprehensive and systematic review of the literature for the summarization of pharmacokinetic parameters would be effective to explore the new safe uses of propranolol in different scenarios, without exposing humans and using virtual-human modeling approaches.

Objective: This review encompasses physicochemical properties, pharmacokinetics and drug-drug interaction data of propranolol collected from various studies.

Methods: Clinical pharmacokinetic studies on propranolol were screened using Medline and Google Scholar databases. Eighty-three clinical trials, in which pharmacokinetic profiles and plasma time concentration were available after oral or IV administration, were included in the review.

Results: The study depicts that propranolol is well absorbed after oral administration. It has dose-dependent bioavailability, and a 2-fold increase in dose results in a 2.5-fold increase in the area under the curve, a 1.3-fold increase in the time to reach maximum plasma concentration and finally, 2.2 and 1.8-fold increase in maximum plasma concentration in both immediate and long-acting formulations, respectively. Propranolol is a substrate of CYP2D6, CYP1A2 and CYP2C19, retaining potential pharmacokinetic interactions with co-administered drugs. Age, gender, race and ethnicity do not alter its pharmacokinetics. However, in renal and hepatic impairment, it needs a dose adjustment.

Conclusion: Physiochemical and pooled pharmacokinetic parameters of propranolol are beneficial to establish physiologically based pharmacokinetic modeling among the diseased population.

Keywords: Propranolol, β-adrenoceptor blocker, physiologically based pharmacokinetics, drug interactions, drug disposition, ADME.

« Previous Next »
Graphical Abstract

[1]
Stapleton, M.P. Sir James Black and propranolol. The role of the basic sciences in the history of cardiovascular pharmacology. Tex. Heart Inst. J., 1997, 24(4), 336-342.
[PMID: 9456487]
[2]
Ahlquist, R.P.; Frieden, J.; Ahlquist, R.P. Present state of alpha and beta adrenergic drugs III.Beta blocking agents Am. Heart J., 1977, 93(1), 117-120.
[http://dx.doi.org/10.1016/S0002-8703(77)80180-4] [PMID: 12653]
[3]
Al-Majed, A.A.; Bakheit, A.H.; Aziz, H.A.A.; Alajmi, F.M.; AlRabiah, H. Propranolol.Profiles of Drug Substances, Excipients and Related Methodology; Elsevier, 2017, Vol. 42, pp. 287-338.
[4]
Mansur, A.P.; Avakian, S.D.; Paula, R.S.; Donzella, H.; Santos, S.R.; Ramires, J.A. Pharmacokinetics and pharmacodynamics of propranolol in hypertensive patients after sublingual administration: systemic availability. Braz. J. Med. Biol. Res., 1998, 31(5), 691-696.
[http://dx.doi.org/10.1590/S0100-879X1998000500014] [PMID: 9698776]
[5]
Schure, A.Y.; DiNardo, J.A. Cardiac Physiology and Pharmacology. In: A Practice of Anesthesia for Infants and Children; Elsevier, 2019; pp. 424-457.e17.
[6]
Gordon, S.G.; Kittleson, M.D. Drugs used in the management of heart disease and cardiac arrhythmias. Small animal clinical pharmacology, 2008, 2, 412-418.
[7]
Padula, C.; Nicoli, S.; Pescina, S.; Santi, P. Thin polymeric films for the topical delivery of propranolol. Colloids Surf. B Biointerfaces, 2019, 174, 582-586.
[http://dx.doi.org/10.1016/j.colsurfb.2018.11.022] [PMID: 30502670]
[8]
Xu, X.; Guo, X.; De Stefano, V.; Silva-Junior, G.; Goyal, H.; Bai, Z.; Zhao, Q.; Qi, X. Nonselective beta-blockers and development of portal vein thrombosis in liver cirrhosis: a systematic review and meta-analysis. Hepatol. Int., 2019, 13(4), 468-481.
[http://dx.doi.org/10.1007/s12072-019-09951-6] [PMID: 31175581]
[9]
Armstead, W.M.; Vavilala, M.S. Propranolol protects cerebral autoregulation and reduces hippocampal neuronal cell death through inhibition of interleukin-6 upregulation after traumatic brain injury in pigs. Br. J. Anaesth., 2019, 123(5), 610-617.
[http://dx.doi.org/10.1016/j.bja.2019.07.017] [PMID: 31542162]
[10]
Chenel, M.; Bouzom, F.; Aarons, L.; Ogungbenro, K. Drug-drug interaction predictions with PBPK models and optimal multiresponse sampling time designs: application to midazolam and a phase I compound. Part 1: comparison of uniresponse and multiresponse designs using PopDes. J. Pharmacokinet. Pharmacodyn., 2008, 35(6), 635-659.
[http://dx.doi.org/10.1007/s10928-008-9104-6] [PMID: 19130188]
[11]
Colbers, A.; Greupink, R.; Litjens, C.; Burger, D.; Russel, F.G. Physiologically based modelling of darunavir/ritonavir pharmacokinetics during pregnancy. Clin. Pharmacokinet., 2016, 55(3), 381-396.
[http://dx.doi.org/10.1007/s40262-015-0325-8] [PMID: 26369773]
[12]
Parrott, N.; Davies, B.; Hoffmann, G.; Koerner, A.; Lave, T.; Prinssen, E.; Theogaraj, E.; Singer, T. Development of a physiologically based model for oseltamivir and simulation of pharmacokinetics in neonates and infants. Clin. Pharmacokinet., 2011, 50(9), 613-623.
[http://dx.doi.org/10.2165/11592640-000000000-00000] [PMID: 21827216]
[13]
Giudicelli, J.F.; Richer, C.; Chauvin, M.; Idrissi, N.; Berdeaux, A. Comparative beta-adrenoceptor blocking effects and pharmacokinetics of penbutolol and propranolol in man. Br. J. Clin. Pharmacol., 1977, 4(2), 135-140.
[http://dx.doi.org/10.1111/j.1365-2125.1977.tb00684.x] [PMID: 16632]
[14]
Salako, L.A.; Falase, A.O.; Aderounmu, A.F. Comparative beta-adrenoreceptor-blocking effects and pharmacokinetics or propranolol and pindolol in hypertensive Africans. Clin. Sci. (Lond.), 1979, 57(Suppl. 5), 393s-396s.
[http://dx.doi.org/10.1042/cs057393s] [PMID: 232026]
[15]
Leahey, W.J.; Neill, J.D.; Varma, M.P.; Shanks, R.G. Comparison of the efficacy and pharmacokinetics of conventional propranolol and a long acting preparation of propranolol. Br. J. Clin. Pharmacol., 1980, 9(1), 33-40.
[http://dx.doi.org/10.1111/j.1365-2125.1980.tb04793.x] [PMID: 7356891]
[16]
Regårdh, C.G.; Johnsson, G.; Jordö, L.; Lungborg, P.; Persson, B.A.; Rönn, O. Plasma concentrations and beta-blocking effects in normal volunteers after intravenous doses of metoprolol and propranolol. J. Cardiovasc. Pharmacol., 1980, 2(6), 715-723.
[http://dx.doi.org/10.1097/00005344-198011000-00002] [PMID: 6160322]
[17]
McAinsh, J.; Baber, N.S.; Holmes, B.F.; Young, J.; Ellis, S.H. Bioavailability of sustained release propranolol formulations. Biopharm. Drug Dispos., 1981, 2(1), 39-48.
[http://dx.doi.org/10.1002/bdd.2510020105] [PMID: 7236870]
[18]
Mould, G.P.; Clough, J.; Morris, B.A.; Stout, G.; Marks, V. A propranolol radioimmunoassay and its use in the study of its pharmacokinetics following low doses. Biopharm. Drug Dispos., 1981, 2(1), 49-57.
[http://dx.doi.org/10.1002/bdd.2510020106] [PMID: 7236871]
[19]
McAinsh, J.; Baber, N.S.; Smith, R.; Young, J. Pharmacokinetic and pharmacodynamic studies with long-acting propranolol. Br. J. Clin. Pharmacol., 1978, 6(2), 115-121.
[http://dx.doi.org/10.1111/j.1365-2125.1978.tb00835.x] [PMID: 678387]
[20]
McAinsh, J.; Holmes, B.F.; Baber, N.S.; Young, J. Bioavailability of propranolol and bendrofluazide formulations. Biopharm. Drug Dispos., 1981, 2(2), 167-175.
[http://dx.doi.org/10.1002/bdd.2510020209] [PMID: 7248480]
[21]
Charles, B.G.; Renshaw, P.J.; Kay, J.J.; Ravenscroft, P.J. Effect of metoclopramide on the bioavailability of long-acting propranolol. Br. J. Clin. Pharmacol., 1981, 11(5), 517-518.
[http://dx.doi.org/10.1111/j.1365-2125.1981.tb01159.x] [PMID: 7272164]
[22]
Drummer, O.H.; McNeil, J.; Pritchard, E.; Louis, W.J. Combined high-performance liquid chromatographic procedure for measuring 4-hydroxypropranolol and propranolol in plasma: pharmacokinetic measurements following conventional and slow-release propranolol administration. J. Pharm. Sci., 1981, 70(9), 1030-1032.
[http://dx.doi.org/10.1002/jps.2600700916] [PMID: 6101148]
[23]
Aro, A.; Anttila, M.; Korhonen, T.; Sundquist, H. Pharmacokinetics of propranolol and sotalol in hyperthyroidism. Eur. J. Clin. Pharmacol., 1982, 21(5), 373-377.
[http://dx.doi.org/10.1007/BF00542321] [PMID: 7075642]
[24]
Hitzenberger, G.; Fitscha, P.; Beveridge, T.; Nüesch, E.; Pacha, W. Effects of age and smoking on the pharmacokinetics of pindolol and propranolol. Br. J. Clin. Pharmacol., 1982, 13(Suppl. 2), 217S-222S.
[http://dx.doi.org/10.1111/j.1365-2125.1982.tb01914.x] [PMID: 7104143]
[25]
Roscoe, R.; Cooper, J.; Wilson, T.W.; Joshi, N.N.; Midha, K.K. The relative bioavailability of a commercial propranolol hydrochloride tablet in man. Biopharm. Drug Dispos., 1982, 3(2), 105-114.
[http://dx.doi.org/10.1002/bdd.2510030204] [PMID: 7104460]
[26]
Sandle, G.I.; Ward, A.; Rawlins, M.D.; Record, C.O. Propranolol absorption in untreated coeliac disease. Clin. Sci. (Lond.), 1982, 63(1), 81-85.
[http://dx.doi.org/10.1042/cs0630081] [PMID: 7083769]
[27]
Wilson, T.W.; Firor, W.B.; Johnson, G.E.; Holmes, G.I.; Tsianco, M.C.; Huber, P.B.; Davies, R.O. Timolol and propranolol: bioavailability, plasma concentrations, and beta blockade. Clin. Pharmacol. Ther., 1982, 32(6), 676-685.
[http://dx.doi.org/10.1038/clpt.1982.223] [PMID: 7140133]
[28]
Smith, M.T.; Livingstone, I.; Eadie, M.J.; Hooper, W.D.; Triggs, E.J. Chronic propranolol administration during pregnancy. Maternal pharmacokinetics. Eur. J. Clin. Pharmacol., 1983, 25(4), 481-490.
[http://dx.doi.org/10.1007/BF00542115] [PMID: 6653642]
[29]
Serlin, M.J.; Orme, M.L.; MacIver, M.; Green, G.J.; Sibeon, R.G.; Breckenridge, A.M. The pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol in patients with moderate hypertension. Br. J. Clin. Pharmacol., 1983, 15(5), 519-527.
[http://dx.doi.org/10.1111/j.1365-2125.1983.tb02085.x] [PMID: 6860527]
[30]
Midha, K.K.; Roscoe, R.M.; Wilson, T.W.; Cooper, J.K.; Loo, J.C.; Ho-Ngoc, A.; McGilveray, I.J. Pharmacokinetics of glucuronidation of propranolol following oral administration in humans. Biopharm. Drug Dispos., 1983, 4(4), 331-338.
[http://dx.doi.org/10.1002/bdd.2510040405] [PMID: 6661512]
[31]
Hawksworth, G.; Betts, T.; Crowe, A.; Knight, R.; Nyemitei-Addo, I.; Parry, K.; Petrie, J.C.; Raffle, A.; Parsons, A. Diazepam/beta-adrenoceptor antagonist interactions. Br. J. Clin. Pharmacol., 1984, 17(Suppl. 1), 69S-76S.
[http://dx.doi.org/10.1111/j.1365-2125.1984.tb02431.x] [PMID: 6146341]
[32]
O’Hare, M.F.; Kinney, C.D.; Murnaghan, G.A.; McDevitt, D.G. Pharmacokinetics of propranolol during pregnancy. Eur. J. Clin. Pharmacol., 1984, 27(5), 583-587.
[http://dx.doi.org/10.1007/BF00556896] [PMID: 6519163]
[33]
Wilkinson, R.; Burr, W.A. A comparison of propranolol and nadolol pharmacokinetics and clinical effects in thyrotoxicosis. Am. Heart J., 1984, 108(4 Pt 2), 1160-1167.
[http://dx.doi.org/10.1016/0002-8703(84)90601-X] [PMID: 6148879]
[34]
Cid, E.; Mella, F.; Lucchini, L.; Cárcamo, M.; Monasterio, J. Plasma concentrations and bioavailability of propranolol by oral, rectal, and intravenous administration in man. Biopharm. Drug Dispos., 1986, 7(6), 559-566.
[http://dx.doi.org/10.1002/bdd.2510070605] [PMID: 3828485]
[35]
Kambara, H.; Kinoshita, M.; Hirota, Y.; Kadota, K.; Sawamura, M.; Saito, T.; Kawai, C. Effect on exercise tolerance and pharmacokinetics of conventional and sustained release preparations of propranolol in patients with angina pectoris--a double-blind cross-over study. Jpn. Circ. J., 1984, 48(10), 1066-1073.
[http://dx.doi.org/10.1253/jcj.48.1066] [PMID: 6387210]
[36]
Maury, M.; Berdeaux, A.; Kher, A.; Duhaze, P.; Giudicelli, J.F. Comparative beta-adrenoceptor blocking effect and pharmacokinetics of bucindolol and propranolol in man. Eur. J. Clin. Pharmacol., 1985, 27(6), 649-656.
[http://dx.doi.org/10.1007/BF00547043] [PMID: 2859199]
[37]
Dunn, J.M.; Groth, P.E.; DeSimone, A. Once-daily propranolol. Lancet, 1985, 2(8465), 1183.
[http://dx.doi.org/10.1016/S0140-6736(85)92701-1] [PMID: 2865633]
[38]
Dey, M.; Brisson, J.; Davis, G.; Enever, R.; Pray, K.; Zaim, B.; Dvornik, D. Relationship between plasma propranolol concentration and dose in young, healthy volunteers. Biopharm. Drug Dispos., 1986, 7(2), 103-111.
[http://dx.doi.org/10.1002/bdd.2510070202] [PMID: 3708118]
[39]
Williams, F.M.; Leeser, J.E.; Rawlins, M.D. Pharmacodynamics and pharmacokinetics of single doses of ketanserin and propranolol alone and in combination in healthy volunteers. Br. J. Clin. Pharmacol., 1986, 22(3), 301-308.
[http://dx.doi.org/10.1111/j.1365-2125.1986.tb02891.x] [PMID: 3768242]
[40]
Henry, D.; Brent, P.; Whyte, I.; Mihaly, G.; Devenish-Meares, S. Propranolol steady-state pharmacokinetics are unaltered by omeprazole. Eur. J. Clin. Pharmacol., 1987, 33(4), 369-373.
[http://dx.doi.org/10.1007/BF00637632] [PMID: 3443142]
[41]
Garg, D.C.; Jallad, N.S.; Mishriki, A.; Chalavarya, G.; Kraml, M.; Fencik, M.; Weidler, D.J. Comparative pharmacodynamics and pharmacokinetics of conventional and long-acting propranolol. J. Clin. Pharmacol., 1987, 27(5), 390-396.
[http://dx.doi.org/10.1002/j.1552-4604.1987.tb03036.x] [PMID: 3693583]
[42]
Marino, M.R.; Dey, M.; Garg, D.C.; Jallad, N.S.; Dorick, D.M.; Martinez, J.J.; Weidler, D.J. Pharmacokinetics and pharmacodynamics of long-acting propranolol 60-mg capsules: a comparative evaluation. J. Clin. Pharmacol., 1987, 27(11), 885-891.
[http://dx.doi.org/10.1002/j.1552-4604.1987.tb05584.x] [PMID: 3429696]
[43]
Huang, S.M.; Weintraub, H.S.; Marriott, T.B.; Marinan, B.; Abels, R. Etintidine-propranolol interaction study in humans. J. Pharmacokinet. Biopharm., 1987, 15(6), 557-568.
[http://dx.doi.org/10.1007/BF01068412] [PMID: 2897462]
[44]
Levine, M.A.; Ogilvie, R.I.; Leenen, F.H. Pharmacokinetic and pharmacodynamic interactions between nisoldipine and propranolol. Clin. Pharmacol. Ther., 1988, 43(1), 39-48.
[http://dx.doi.org/10.1038/clpt.1988.9] [PMID: 2826066]
[45]
Sharoky, M.; Perkal, M.; Turner, R.; Lesko, L.J. Steady state relative bioavailability and pharmacokinetics of oral propranolol in black and white North Americans. Biopharm. Drug Dispos., 1988, 9(5), 447-456.
[http://dx.doi.org/10.1002/bod.2510090503] [PMID: 3224162]
[46]
Belz, G.G.; Essig, J.; Kleinbloesem, C.H.; Hoogkamer, J.F.; Wiegand, U.W.; Wellstein, A. Interactions between cilazapril and propranolol in man; plasma drug concentrations, hormone and enzyme responses, haemodynamics, agonist dose-effect curves and baroreceptor reflex. Br. J. Clin. Pharmacol., 1988, 26(5), 547-556.
[http://dx.doi.org/10.1111/j.1365-2125.1988.tb05294.x] [PMID: 2974715]
[47]
Belz, G.G.; Essig, J.; Erb, K.; Breithaupt, K.; Hoogkamer, J.F.; Kneer, J.; Kleinbloesem, C.H. Pharmacokinetic and pharmacodynamic interactions between the ACE inhibitor cilazapril and beta-adrenoceptor antagonist propranolol in healthy subjects and in hypertensive patients. Br. J. Clin. Pharmacol., 1989, 27(Suppl. 2), 317S-322S.
[http://dx.doi.org/10.1111/j.1365-2125.1989.tb03498.x] [PMID: 2527545]
[48]
Eldon, M.A.; Kinkel, A.W.; Daniel, J.E.; Latts, J.R. Bioavailability of propranolol hydrochloride tablet formulations: application of multiple dose crossover studies. Biopharm. Drug Dispos., 1989, 10(1), 69-76.
[http://dx.doi.org/10.1002/bdd.2510100108] [PMID: 2923962]
[49]
Roberts, R.J.; Leff, R.D. Influence of absorbable and nonabsorbable lipids and lipidlike substances on drug bioavailability. Clin. Pharmacol. Ther., 1989, 45(3), 299-304.
[http://dx.doi.org/10.1038/clpt.1989.32] [PMID: 2920504]
[50]
Flouvat, B.; Berlin, I.; Cournot, A.; Robinet, D.; Duchier, J.; Sarmini, H.; Rossi, A. Pharmacokinetic and pharmacodynamic comparison of two doses of long acting propranolol (80 and 160 mg) in healthy subjects. Br. J. Clin. Pharmacol., 1989, 27(5), 539-545.
[http://dx.doi.org/10.1111/j.1365-2125.1989.tb03415.x] [PMID: 2757878]
[51]
Calès, P.; Grasset, D.; Ravaud, A.; Meskens, C.; Blanc, M.; Vinel, J.P.; Cotonat, J.; Pascal, J.P. Pharmacodynamic and pharmacokinetic study of propranolol in patients with cirrhosis and portal hypertension. Br. J. Clin. Pharmacol., 1989, 27(6), 763-770.
[http://dx.doi.org/10.1111/j.1365-2125.1989.tb03438.x] [PMID: 2569324]
[52]
Poirier, J.M.; Le Jeunne, C.; Cheymol, G.; Cohen, A.; Barré, J.; Hugues, F.C. Comparison of propranolol and sotalol pharmacokinetics in obese subjects. J. Pharm. Pharmacol., 1990, 42(5), 344-348.
[http://dx.doi.org/10.1111/j.2042-7158.1990.tb05423.x] [PMID: 1976782]
[53]
Schoors, D.F.; Vercruysse, I.; Musch, G.; Massart, D.L.; Dupont, A.G. Influence of nicardipine on the pharmacokinetics and pharmacodynamics of propranolol in healthy volunteers. Br. J. Clin. Pharmacol., 1990, 29(5), 497-501.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03671.x] [PMID: 2350528]
[54]
Yasuhara, M.; Yatsuzuka, A.; Yamada, K.; Okumura, K.; Hori, R.; Sakurai, T.; Kawai, C. Alteration of propranolol pharmacokinetics and pharmacodynamics by quinidine in man. J. Pharmacobiodyn., 1990, 13(11), 681-687.
[http://dx.doi.org/10.1248/bpb1978.13.681] [PMID: 2093126]
[55]
Hall, S.T.; Harding, S.M.; Hassani, H.; Keene, O.N.; Pellegatti, M. The pharmacokinetic and pharmacodynamic interaction between lacidipine and propranolol in healthy volunteers. J. Cardiovasc. Pharmacol., 1991, 18(Suppl. 11), S13-S17.
[http://dx.doi.org/10.1097/00005344-199102001-00003] [PMID: 1725444]
[56]
Murdoch, D.L.; Thomson, G.D.; Thompson, G.G.; Murray, G.D.; Brodie, M.J.; McInnes, G.T. Evaluation of potential pharmacodynamic and pharmacokinetic interactions between verapamil and propranolol in normal subjects. Br. J. Clin. Pharmacol., 1991, 31(3), 323-332.
[http://dx.doi.org/10.1111/j.1365-2125.1991.tb05536.x] [PMID: 2054272]
[57]
Bennett, P.N.; Fenn, G.C.; Notarianni, L.J.; Lee, C.E. Misoprostol does not alter the pharmacokinetics of propranolol. Postgrad. Med. J., 1991, 67(787), 455-457.
[http://dx.doi.org/10.1136/pgmj.67.787.455] [PMID: 1906610]
[58]
Dimmitt, D.C.; Yu, D.K.; Elvin, A.T.; Giesing, D.H.; Lanman, R.C. Pharmacokinetics of diltiazem and propranolol when administered alone and in combination. Biopharm. Drug Dispos., 1991, 12(7), 515-523.
[http://dx.doi.org/10.1002/bdd.2510120705] [PMID: 1932613]
[59]
Stoschitzky, K.; Lindner, W.; Egginger, G.; Brunner, F.; Obermayer-Pietsch, B.; Passath, A.; Klein, W. Racemic (R,S)-propranolol versus half-dosed optically pure (S)-propranolol in humans at steady state: Hemodynamic effects, plasma concentrations,and influence on thyroid hormone levels. Clin. Pharmacol. Ther., 1992, 51(4), 445-453.
[http://dx.doi.org/10.1038/clpt.1992.45] [PMID: 1563214]
[60]
Greenblatt, D.J.; Scavone, J.M.; Harmatz, J.S.; Engelhardt, N.; Shader, R.I. Cognitive effects of beta-adrenergic antagonists after single doses: pharmacokinetics and pharmacodynamics of propranolol, atenolol, lorazepam, and placebo. Clin. Pharmacol. Ther., 1993, 53(5), 577-584.
[http://dx.doi.org/10.1038/clpt.1993.73] [PMID: 8098277]
[61]
Shiga, T.; Fujimura, A.; Tateishi, T.; Ohashi, K.; Ebihara, A. Differences of chronopharmacokinetic profiles between propranolol and atenolol in hypertensive subjects. J. Clin. Pharmacol., 1993, 33(8), 756-761.
[http://dx.doi.org/10.1002/j.1552-4604.1993.tb05620.x] [PMID: 8408738]
[62]
Bellissant, E.; Annane, D.; Thuillez, C.; Giudicelli, J.F. Comparison of the effects of dilevalol and propranolol on systemic and regional haemodynamics in healthy volunteers at rest and during exercise. Eur. J. Clin. Pharmacol., 1994, 47(1), 39-47.
[http://dx.doi.org/10.1007/BF00193476] [PMID: 7988622]
[63]
Bleske, B.E.; Welage, L.S.; Touchette, M.A.; Edwards, D.J.; Rodman, D.P.; Shea, M.J. Evaluation of dosage-release formulations on inhibition of drug clearance: effect of sustained- and immediate-release verapamil on propranolol pharmacokinetic parameters. Ther. Drug Monit., 1994, 16(2), 216-220.
[http://dx.doi.org/10.1097/00007691-199404000-00019] [PMID: 8009573]
[64]
Shaw-Stiffel, T.A.; Walker, S.E.; Ogilvie, R.I.; Leenen, F.H. Pharmacokinetic and pharmacodynamic interactions during multiple-dose administration of nisoldipine and propranolol. Clin. Pharmacol. Ther., 1994, 55(6), 661-669.
[http://dx.doi.org/10.1038/clpt.1994.83] [PMID: 8004882]
[65]
Egginger, G.; Lindner, W.; Brunner, G.; Stoschitzky, K. Direct enantioselective determination of (R)- and (S)-propranolol in human plasma. Application to pharmacokinetic studies. J. Pharm. Biomed. Anal., 1994, 12(12), 1537-1545.
[http://dx.doi.org/10.1016/0731-7085(94)00129-4] [PMID: 7696378]
[66]
Vanakoski, J.; Seppälä, T. Effects of a Finnish sauna on the pharmacokinetics and haemodynamic actions of propranolol and captopril in healthy volunteers. Eur. J. Clin. Pharmacol., 1995, 48(2), 133-137.
[http://dx.doi.org/10.1007/BF00192738] [PMID: 7589027]
[67]
Gonzalez, J.P.; Valdivieso, A.; Calvo, R.; Rodríguez-Sasiaín, J.M.; Jimenez, R.; Aguirre, C.; du Souich, P. Influence of vitamin C on the absorption and first pass metabolism of propranolol. Eur. J. Clin. Pharmacol., 1995, 48(3-4), 295-297.
[http://dx.doi.org/10.1007/BF00198315] [PMID: 7589058]
[68]
Bleske, B.E.; Welage, L.S.; Rose, S.; Amidon, G.L.; Shea, M.J. The effect of dosage release formulations on the pharmacokinetics of propranolol stereoisomers in humans. J. Clin. Pharmacol., 1995, 35(4), 374-378.
[http://dx.doi.org/10.1002/j.1552-4604.1995.tb04076.x] [PMID: 7650226]
[69]
Panton, L.B.; Guillen, G.J.; Williams, L.; Graves, J.E.; Vivas, C.; Cediel, M.; Pollock, M.L.; Garzarella, L.; Krumerman, J.; Derendorf, H. The lack of effect of aerobic exercise training on propranolol pharmacokinetics in young and elderly adults. J. Clin. Pharmacol., 1995, 35(9), 885-894.
[http://dx.doi.org/10.1002/j.1552-4604.1995.tb04133.x] [PMID: 8786248]
[70]
Power, J.M.; Morgan, D.J.; McLean, A.J. Effects of sensory (teasing) exposure to food on oral propranolol bioavailability. Biopharm. Drug Dispos., 1995, 16(7), 579-589.
[http://dx.doi.org/10.1002/bdd.2510160706] [PMID: 8785381]
[71]
Salazar, D.E.; Marathe, P.H.; Fulmor, I.E.; Lee, J.S.; Raymond, R.H.; Uderman, H.D. Pharmacokinetic and pharmacodynamic evaluation during coadministration of nefazodone and propranolol in healthy men. J. Clin. Pharmacol., 1995, 35(11), 1109-1118.
[http://dx.doi.org/10.1002/j.1552-4604.1995.tb04035.x] [PMID: 8626885]
[72]
Cheymol, G.; Poirier, J.M.; Carrupt, P.A.; Testa, B.; Weissenburger, J.; Levron, J.C.; Snoeck, E. Pharmacokinetics of beta-adrenoceptor blockers in obese and normal volunteers. Br. J. Clin. Pharmacol., 1997, 43(6), 563-570.
[http://dx.doi.org/10.1046/j.1365-2125.1997.00609.x] [PMID: 9205815]
[73]
Wójcicki, J.; Sulzyc-Bielicka, V.; Kutrzeba, J.; Gawrońska-Szklarz, B.; Droździk, M.; Sterna, Z. Studies on the pharmacokinetics and pharmacodynamics of propranolol in hyperlipidemia. J. Clin. Pharmacol., 1999, 39(8), 826-833.
[http://dx.doi.org/10.1177/00912709922008498] [PMID: 10434235]
[74]
Schepke, M.; Raab, P.; Hoppe, A.; Brensing, K.; Paar, D.; Potyka, U.; Sauerbruch, T. Propranolol stereoisomer plasma concentrations and portal haemodynamic response in patients with liver cirrhosis. Aliment. Pharmacol. Ther., 1999, 13(11), 1451-1458.
[http://dx.doi.org/10.1046/j.1365-2036.1999.00622.x] [PMID: 10571601]
[75]
Wójcicki, J.; Wojciechowski, G.; Wójcicki, M.; Kostyrka, R.; Sterna, R.; Gawronska-Szklarz, B.; Pawlik, A.; Drozdzik, M.; Kozlowski, K. Pharmacokinetics of propranolol and atenolol in patients after partial gastric resection: a comparative study. Eur. J. Clin. Pharmacol., 2000, 56(1), 75-79.
[http://dx.doi.org/10.1007/s002280050724] [PMID: 10853882]
[76]
Wójcicki, J.; Jaroszynska, M.; Droździk, M.; Pawlik, A.; Gawrońska-Szklarz, B.; Sterna, R. Comparative pharmacokinetics and pharmacodynamics of propranolol and atenolol in normolipaemic and hyperlipidaemic obese subjects. Biopharm. Drug Dispos., 2003, 24(5), 211-218.
[http://dx.doi.org/10.1002/bdd.357] [PMID: 12784321]
[77]
Avram, M.J.; Krejcie, T.C.; Henthorn, T.K.; Niemann, C.U. Beta-adrenergic blockade affects initial drug distribution due to decreased cardiac output and altered blood flow distribution. J. Pharmacol. Exp. Ther., 2004, 311(2), 617-624.
[http://dx.doi.org/10.1124/jpet.104.070094] [PMID: 15197245]
[78]
Mehuys, E.; Remon, J.P.; Korst, A.; Van Bortel, L.; Mols, R.; Augustijns, P.; Porter, C.; Vervaet, C. Human bioavailability of propranolol from a matrix-in-cylinder system with a HPMC-Gelucire core. J. Control. Release, 2005, 107(3), 523-536.
[http://dx.doi.org/10.1016/j.jconrel.2005.06.019] [PMID: 16055224]
[79]
Williams, F.N.; Herndon, D.N.; Kulp, G.A.; Jeschke, M.G. Propranolol decreases cardiac work in a dose-dependent manner in severely burned children. Surgery, 2011, 149(2), 231-239.
[http://dx.doi.org/10.1016/j.surg.2010.05.015] [PMID: 20598332]
[80]
Salman, S.A.; Amrah, S.; Wahab, M.S.; Ismail, Z.; Ismail, R.; Yuen, K.H.; Gan, S.H. Modification of propranolol’s bioavailability by Eurycoma longifolia water-based extract. J. Clin. Pharm. Ther., 2010, 35(6), 691-696.
[http://dx.doi.org/10.1111/j.1365-2710.2009.01147.x] [PMID: 21054461]
[81]
Filippi, L.; Cavallaro, G.; Fiorini, P.; Daniotti, M.; Benedetti, V.; Cristofori, G.; Araimo, G.; Ramenghi, L.; La Torre, A.; Fortunato, P.; Pollazzi, L.; la Marca, G.; Malvagia, S.; Bagnoli, P.; Ristori, C.; Dal Monte, M.; Bilia, A.R.; Isacchi, B.; Furlanetto, S.; Tinelli, F.; Cioni, G.; Donzelli, G.; Osnaghi, S.; Mosca, F. Study protocol: safety and efficacy of propranolol in newborns with Retinopathy of Prematurity (PROP-ROP): ISRCTN18523491. BMC Pediatr., 2010, 10, 83.
[http://dx.doi.org/10.1186/1471-2431-10-83] [PMID: 21087499]
[82]
Venkata Srikanth, M.; Songa, A.S.; Nali, S.R.; Battu, J.R.; Kolapalli, V.R. Thermal sintering: a novel technique used in the design, optimization and biopharmaceutical evaluation of propranolol HCl gastric floating tablets. Drug Dev. Ind. Pharm., 2014, 40(1), 33-45.
[http://dx.doi.org/10.3109/03639045.2012.744416] [PMID: 23317339]
[83]
Wang, Y.; Wang, Z.; Zuo, Z.; Tomlinson, B.; Lee, B.T.; Bolger, M.B.; Chow, M.S. Clinical pharmacokinetics of buffered propranolol sublingual tablet (Promptol™)-application of a new “physiologically based” model to assess absorption and disposition. AAPS J., 2013, 15(3), 787-796.
[http://dx.doi.org/10.1208/s12248-013-9479-1] [PMID: 23605805]
[84]
Taegtmeyer, A.B.; Haschke, M.; Tchambaz, L.; Buylaert, M.; Tschöpl, M.; Beuers, U.; Drewe, J.; Krähenbühl, S. A study of the relationship between serum bile acids and propranolol pharmacokinetics and pharmacodynamics in patients with liver cirrhosis and in healthy controls. PLoS One, 2014, 9(6)e97885
[http://dx.doi.org/10.1371/journal.pone.0097885] [PMID: 24906133]
[85]
Manitpisitkul, P.; Curtin, C.R.; Shalayda, K.; Wang, S.S.; Ford, L.; Heald, D. Pharmacokinetic interactions between topiramate and diltiazem, hydrochlorothiazide, or propranolol. Clin. Pharmacol. Drug Dev., 2014, 3(5), 378-387.
[http://dx.doi.org/10.1002/cpdd.107] [PMID: 27129011]
[86]
Park, S.; Ryu, S.; Oh, W.Y.; Hwang, I.Y.; Lee, J.G.; Park, Z.W.; Choi, S.E. Population Pharmacokinetics Of Propranolol in Patients with Liver Cirrhosis. Clin. Ther., 2017, 39(8), e51-e52.
[http://dx.doi.org/10.1016/j.clinthera.2017.05.159]
[87]
El-Shabrawi, M.; Hassanin, F. Propranolol safety profile in children. Curr. Drug Saf., 2011, 6(4), 259-266.
[http://dx.doi.org/10.2174/157488611798280889] [PMID: 22129321]
[88]
McFarland, J.W.; Avdeef, A.; Berger, C.M.; Raevsky, O.A. Estimating the water solubilities of crystalline compounds from their chemical structures alone. J. Chem. Inf. Comput. Sci., 2001, 41(5), 1355-1359.
[http://dx.doi.org/10.1021/ci0102822] [PMID: 11604037]
[89]
Teksin, Z.S.; Seo, P.R.; Polli, J.E. Comparison of drug permeabilities and BCS classification: three lipid-component PAMPA system method versus Caco-2 monolayers. AAPS J., 2010, 12(2), 238-241.
[http://dx.doi.org/10.1208/s12248-010-9176-2] [PMID: 20224985]
[90]
Cid, E.; Mella, F.; Lucchini, L.; Carcamo, M.; Monasterio, J. [Bioavailability of propranolol administered by the rectal route in man]. Therapie, 1985, 40(6), 447-449. [Bioavailability of propranolol administered by the rectal route in man].
[PMID: 4089786]
[91]
Vogelpoel, H.; Welink, J.; Amidon, G.L.; Junginger, H.E.; Midha, K.K.; Möller, H.; Olling, M.; Shah, V.P.; Barends, D.M. Biowaiver monographs for immediate release solid oral dosage forms based on biopharmaceutics classification system (BCS) literature data: verapamil hydrochloride, propranolol hydrochloride, and atenolol. J. Pharm. Sci., 2004, 93(8), 1945-1956.
[http://dx.doi.org/10.1002/jps.20131] [PMID: 15236445]
[92]
Taylor, E.A.; Turner, P. The distribution of propranolol, pindolol and atenolol between human erythrocytes and plasma. Br. J. Clin. Pharmacol., 1981, 12(4), 543-548.
[http://dx.doi.org/10.1111/j.1365-2125.1981.tb01263.x] [PMID: 7295488]
[93]
Kelly, J.G.; McDevitt, D.G. Plasma protein binding of propranolol and isoprenaline in hyperthyroidism and hypothyroidism. Br. J. Clin. Pharmacol., 1978, 6(2), 123-127.
[http://dx.doi.org/10.1111/j.1365-2125.1978.tb00836.x] [PMID: 678388]
[94]
Paterson, J.; Conolly, M.; Dollery, C.; Hayes, A.; Cooper, R. The pharmacodynamics and metabolism of propranolol in man Pharmacologia clinica, 1970, 2(3), 127-133.
[95]
Masubuchi, Y.; Hosokawa, S.; Horie, T.; Suzuki, T.; Ohmori, S.; Kitada, M.; Narimatsu, S. Cytochrome P450 isozymes involved in propranolol metabolism in human liver microsomes. The role of CYP2D6 as ring-hydroxylase and CYP1A2 as N-desisopropylase. Drug Metab. Dispos., 1994, 22(6), 909-915.
[PMID: 7895609]
[96]
Del Frari, L.; Léauté-Labrèze, C.; Guibaud, L.; Barbarot, S.; Lacour, J.P.; Chaumont, C.; Delarue, A.; Voisard, J.J.; Brunner, V. Propranolol pharmacokinetics in infants treated for Infantile Hemangiomas requiring systemic therapy: Modeling and dosing regimen recommendations. Pharmacol. Res. Perspect., 2018, 6(3)e00399
[http://dx.doi.org/10.1002/prp2.399] [PMID: 29736244]
[97]
Johnson, T.N.; Boussery, K.; Rowland-Yeo, K.; Tucker, G.T.; Rostami-Hodjegan, A. A semi-mechanistic model to predict the effects of liver cirrhosis on drug clearance. Clin. Pharmacokinet., 2010, 49(3), 189-206.
[http://dx.doi.org/10.2165/11318160-000000000-00000] [PMID: 20170207]
[98]
Byrne, A.J.; McNeil, J.J.; Harrison, P.M.; Louis, W.; Tonkin, A.M.; McLean, A.J. Stable oral availability of sustained release propranolol when co-administered with hydralazine or food: evidence implicating substrate delivery rate as a determinant of presystemic drug interactions. Br. J. Clin. Pharmacol., 1984, 17(S1)(Suppl. 1), 45S-50S.
[http://dx.doi.org/10.1111/j.1365-2125.1984.tb02427.x] [PMID: 6743474]
[99]
Walle, T.; Byington, R.P.; Furberg, C.D.; McIntyre, K.M.; Vokonas, P.S. Biologic determinants of propranolol disposition: results from 1308 patients in the Beta-Blocker Heart Attack Trial. Clin. Pharmacol. Ther., 1985, 38(5), 509-518.
[http://dx.doi.org/10.1038/clpt.1985.216] [PMID: 4053488]
[100]
Livingstone, I.; Craswell, P.W.; Bevan, E.B.; Smith, M.T.; Eadie, M.J. Propranolol in pregnancy three year prospective study. Clin. Exp. Hypertens. B, 1983, 2(2), 341-350.
[http://dx.doi.org/10.3109/10641958309006092] [PMID: 6872291]
[101]
Smith, M.T.; Livingstone, I.; Eadie, M.J.; Hooper, W.D.; Triggs, E.J. Metabolism of propranolol in the human maternal-placental-foetal unit. Eur. J. Clin. Pharmacol., 1983, 24(6), 727-732.
[http://dx.doi.org/10.1007/BF00607078] [PMID: 6884410]
[102]
Brown, C.M.; Garovic, V.D. Drug treatment of hypertension in pregnancy. Drugs, 2014, 74(3), 283-296.
[http://dx.doi.org/10.1007/s40265-014-0187-7] [PMID: 24554373]
[103]
Shanks, R.G.; Hadden, D.R.; Lowe, D.C.; McDevitt, D.G.; Montgomery, D.A. Controlled trial of propranolol in thyrotoxicosis. Lancet, 1969, 1(7603), 993-994.
[http://dx.doi.org/10.1016/S0140-6736(69)91797-8] [PMID: 4181181]
[104]
Calès, P.; Caillau, H.; Crambes, O.; Vinel, J.P.; Desmorat, H.; Rocher, I.; Jung, L.; Urien, S.; Brouard, R.; Pascal, J.P. Hemodynamic and pharmacokinetic study of tertatolol in patients with alcoholic cirrhosis and portal hypertension. J. Hepatol., 1993, 19(1), 43-50.
[http://dx.doi.org/10.1016/S0168-8278(05)80174-6] [PMID: 7905493]
[105]
Verbeeck, R.K. Pharmacokinetics and dosage adjustment in patients with hepatic dysfunction. Eur. J. Clin. Pharmacol., 2008, 64(12), 1147-1161.
[http://dx.doi.org/10.1007/s00228-008-0553-z] [PMID: 18762933]
[106]
Grendelmeier, I. [Renal hypertension--the role of the kidneys in blood pressure regulation and the kidneys as end organ]. Ther. Umsch., 2015, 72(6), 369-374.
[http://dx.doi.org/10.1024/0040-5930/a000688] [PMID: 26098186]
[107]
Wood, A.J.; Vestal, R.E.; Spannuth, C.L.; Stone, W.J.; Wilkinson, G.R.; Shand, D.G. Propranolol disposition in renal failure. Br. J. Clin. Pharmacol., 1980, 10(6), 561-566.
[http://dx.doi.org/10.1111/j.1365-2125.1980.tb00511.x] [PMID: 7470370]
[108]
Thompson, F.D.; Joekes, A.M.; Foulkes, D.M. Pharmacodynamics of propranolol in renal failure. BMJ, 1972, 2(5811), 434-436.
[http://dx.doi.org/10.1136/bmj.2.5811.434] [PMID: 5031656]
[109]
Ponikowski, P.; Voors, A.A.; Anker, S.D.; Bueno, H.; Cleland, J.G.; Coats, A.J.; Falk, V.; González-Juanatey, J.R.; Harjola, V.P.; Jankowska, E.A.; Jessup, M.; Linde, C.; Nihoyannopoulos, P.; Parissis, J.T.; Pieske, B.; Riley, J.P.; Rosano, G.M.; Ruilope, L.M.; Ruschitzka, F.; Rutten, F.H.; van der Meer, P. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur. J. Heart Fail., 2016, 18(8), 891-975.
[http://dx.doi.org/10.1002/ejhf.592] [PMID: 27207191]
[110]
Peet, M.; Middlemiss, D.N.; Yates, R.A. Propranolol in schizophrenia. II. Clinical and biochemical aspects of combining propranolol with chlorpromazine. Br. J. Psychiatry, 1981, 139(2), 112-117.
[http://dx.doi.org/10.1192/bjp.139.2.112] [PMID: 7030443]
[111]
Bax, N.; Lennard, M.; Al-Asady, S.; Deacon, C.; Tucker, G.; Woods, H. Inhibition of drug metabolism by β-adrenoceptor antagonists. Drugs, 1983, 25(2), 121-126.
[http://dx.doi.org/10.2165/00003495-198300252-00036]
[112]
Scott, A.K.; Park, B.K.; Breckenridge, A.M. Interaction between warfarin and propranolol. Br. J. Clin. Pharmacol., 1984, 17(5), 559-564.
[http://dx.doi.org/10.1111/j.1365-2125.1984.tb02390.x] [PMID: 6733003]
[113]
Tyrer, P.J.; Lader, M.H. Response to propranolol and diazepam in somatic and psychic anxiety. BMJ, 1974, 2(5909), 14-16.
[http://dx.doi.org/10.1136/bmj.2.5909.14] [PMID: 4595181]
[114]
Cameron, H.A.; Waller, P.C.; Ramsay, L.E. Ketanserin in essential hypertension: use as monotherapy and in combination with a diuretic or beta-adrenoceptor antagonist. Br. J. Clin. Pharmacol., 1987, 24(6), 705-711.
[http://dx.doi.org/10.1111/j.1365-2125.1987.tb03235.x] [PMID: 2894215]
[115]
Meuldermans, W.; Hendrickx, J.; Woestenborghs, R.; Van Peer, A.; Lauwers, W.; De Cree, J.; Heykants, J. Absorption, metabolism and excretion of ketanserin in man after oral administration. Arzneimittelforschung, 1988, 38(6), 789-794.
[PMID: 3178919]
[116]
Budzyński, J.; Pulkowski, G.; Suppan, K.; Fabisiak, J.; Majer, M.; Kłopocka, M.; Galus-Pulkowska, B.; Wasielewski, M. Improvement in health-related quality of life after therapy with omeprazole in patients with coronary artery disease and recurrent angina-like chest pain. A double-blind, placebo-controlled trial of the SF-36 survey. Health Qual. Life Outcomes, 2011, 9(1), 77.
[http://dx.doi.org/10.1186/1477-7525-9-77] [PMID: 21939510]
[117]
Ogawa, R.; Echizen, H. Drug-drug interaction profiles of proton pump inhibitors. Clin. Pharmacokinet., 2010, 49(8), 509-533.
[http://dx.doi.org/10.2165/11531320-000000000-00000] [PMID: 20608754]
[118]
Karol, M.D.; Locke, C.S.; Cavanaugh, J.H. Lack of interaction between lansoprazole and propranolol, a pharmacokinetic and safety assessment. J. Clin. Pharmacol., 2000, 40(3), 301-308.
[http://dx.doi.org/10.1177/00912700022008856] [PMID: 10709160]
[119]
Popescu, S.M.; Nechifor, M.; Baniceru, M.; Croitoru, O.; Popescu, F. Effect of propranolol on mepivacaine serum concentrations in dental practice. Oral Surg. Oral Med. Oral Pathol. Oral Radiol. Endod., 2008, 105(4), e19-e23.
[http://dx.doi.org/10.1016/j.tripleo.2007.12.010] [PMID: 18329563]
[120]
Fleishaker, J.C.; Sisson, T.A.; Carel, B.J.; Azie, N.E. Lack of pharmacokinetic interaction between the antimigraine compound, almotriptan, and propranolol in healthy volunteers. Cephalalgia, 2001, 21(1), 61-65.
[http://dx.doi.org/10.1046/j.1468-2982.2001.00151.x] [PMID: 11298665]
[121]
Peck, R.W.; Seaber, E.J.; Dixon, R.; Gillotin, C.G.; Weatherley, B.C.; Layton, G.; Posner, J. The interaction between propranolol and the novel antimigraine agent zolmitriptan (311C90). Br. J. Clin. Pharmacol., 1997, 44(6), 595-599.
[http://dx.doi.org/10.1046/j.1365-2125.1997.t01-1-00632.x] [PMID: 9431839]
[122]
Nemire, R.E.; Toledo, C.A.; Ramsay, R.E. A pharmacokinetic study to determine the drug interaction between valproate and propranolol. Pharmacotherapy, 1996, 16(6), 1059-1062.
[PMID: 8947979]
[123]
van Griensven, J.M.; Seibert-Grafe, M.; Schoemaker, H.C.; Frölich, M.; Cohen, A.F. The pharmacokinetic and pharmacodynamic interactions of ramipril with propranolol. Eur. J. Clin. Pharmacol., 1993, 45(3), 255-260.
[http://dx.doi.org/10.1007/BF00315392] [PMID: 8276050]
[124]
Scott, A.K.; Walley, T.; Breckenridge, A.M.; Lacey, L.F.; Fowler, P.A. Lack of an interaction between propranolol and sumatriptan. Br. J. Clin. Pharmacol., 1991, 32(5), 581-584.
[http://dx.doi.org/10.1111/j.1365-2125.1991.tb03955.x] [PMID: 1659437]
[125]
Baraka, O.Z.; Truman, C.A.; Ford, J.M.; Roberts, C.J. The effect of propranolol on paracetamol metabolism in man. Br. J. Clin. Pharmacol., 1990, 29(2), 261-264.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03631.x] [PMID: 2306420]
[126]
Sonne, J.; Døssing, M.; Loft, S.; Olesen, K.L.; Vollmer-Larsen, A.; Victor, M.A.; Hamberg, O.; Thyssen, H. Single dose pharmacokinetics and pharmacodynamics of oral oxazepam during concomitant administration of propranolol and labetalol. Br. J. Clin. Pharmacol., 1990, 29(1), 33-37.
[http://dx.doi.org/10.1111/j.1365-2125.1990.tb03599.x] [PMID: 2297460]

Rights & Permissions Print Cite
Article Metrics
68
4
1
© 2024 Bentham Science Publishers | Privacy Policy